Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00759395 · ClinicalTrials.gov registry record · Phase 2
Study of Antidepressant Efficacy of a Selective, High Affinity Enkephalinergic Agonist in Anxious Major Depressive Disorder (AMDD)
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
NCT00759395 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 22 participants.
The verdict
NCT00759395, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
Study Summary
This study will determine if a highly selective enkephalinergic receptor modulator is effective in the treatment of anxious major depressive disorder.
Interventions
- DRUG Placebo
- DRUG AZD2327
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2009-01 |
| Est. Completion | 2011-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00759395
The ClinicalTrials.gov registry entry for NCT00759395 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00759395 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00759395 about?
NCT00759395 is a clinical study titled "Study of Antidepressant Efficacy of a Selective, High Affinity Enkephalinergic Agonist in Anxious Major Depressive Disorder (AMDD)". This study will determine if a highly selective enkephalinergic receptor modulator is effective in the treatment of anxious major depressive disorder.
What is the current status of trial NCT00759395?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2009-01. Estimated completion is 2011-10.
What interventions are being tested in trial NCT00759395?
The interventions under investigation include: Placebo (DRUG), AZD2327 (DRUG).
Who is sponsoring clinical trial NCT00759395?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.